Company intelligence / Profile preview

Anagenesis Biotechnologies

Strasbourg (Illkirch-Graffenstaden), Alsace, France

Ownership: Private
Development stage: Other

Overview

Anagenesis Biotechnologies is a preclinical-stage biotech company developing innovative stem cell- and reprogrammed cell-based therapies for genetic and age-related muscle degenerative diseases, with a lead focus on Duchenne muscular dystrophy (DMD). Their proprietary P2MCs platform enables the scalable production of muscle cells from stem cells, supporting both cell therapy and small molecule drug discovery. Preclinical proof-of-concept has been demonstrated for muscle diseases using both modalities.

Therapeutic areas: OncologyRare DiseasesMetabolic Disorders
Modalities: Induced pluripotent stem cell derived therapyCell therapySmall molecule
Industry: Biotech

Partnerships

CRISPR Therapeutics

Beyond the preview

Go deeper on Anagenesis Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anagenesis Biotechnologies.

Explore the full profile